VANCOUVER, Washington, Feb. 03, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]
Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same […]
CytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV) VANCOUVER, Washington, Jan. 28, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology […]
VANCOUVER, Washington, Jan 27, 2020 — The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn has […]
CytoDyn, Inc. (OTC: CYDY) Next Super Stock investor conference presentation January 23, 2020 CEO Dr. Nader Pourhassan, Ph.D, discusses CytoDyn’ new $87.5 million licensing deal for commercializing Leronlimab to treat HIV, as well as the […]
VANCOUVER, Washington, Jan 22, 2020 — First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab […]
VANCOUVER, Washington, Jan. 13, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]
VANCOUVER, Washington, Jan. 09, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it […]
Objective clinical responses in these two patients treated with leronlimab (PRO 140) lead to plans for imminent filing of a Breakthrough Therapy Designation Application while trial enrollment efforts continue at much higher pace VANCOUVER, Washington, […]
VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]
VANCOUVER, Washington, Dec. 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]
VANCOUVER, Washington, Dec 03, 2019 — First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 […]
Collaboration will Target a Therapeutic Approach for Treating Asthma and Allergic Diseases NEW YORK, Nov. 26, 2019– Hoth Therapeutics, Inc. (NASDAQ: HOTH), (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological […]
New preclinical data using a humanized mouse model confirms and expands on the potential use of leronlimab in treating this inflammatory syndrome, a common precursor to NASH VANCOUVER, Washington, Nov 21, 2019 — CytoDyn Inc. […]
NEW YORK, Nov. 18, 2019 — Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
